All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (liver )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
Extensive stage SCLC (Es-SCLC) - maintenance (M), nivolumab based treatment vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 451 (N ; all population), 2019 0.84 [0.69; 1.02]
0.84 [0.69 ; 1.02 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable progression or deaths (PFS)detailed results CheckMate 451 (N ; all population), 2019 0.67 [0.56; 0.81]
0.67 [0.56 ; 0.81 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable objective responses (ORR)detailed results CheckMate 451 (N ; all population), 2019 2.93 [1.44; 5.95]
2.93 [1.44 ; 5.95 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable TRAE (any grade)detailed results CheckMate 451 (N ; all population), 2019 1.49 [1.06; 2.08]
1.49 [1.06 ; 2.08 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 451 (N ; all population), 2019 1.59 [0.90; 2.79]
1.59 [0.90 ; 2.79 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 451 (N ; all population), 2019 0.98 [0.06; 15.78]
0.98 [0.06 ; 15.78 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable TRAE leading to discontinuation (any grade)detailed results Out of scale CheckMate 451 (N ; all population), 2019 20.14 [4.80; 84.52]
20.14 [4.80 ; 84.52 ] CheckMate 451 (N ; all population), 2019 1 0% 555 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 18:42 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 194
- treatments: 855,360,719,721,720,842,642,674,1085,863